MétaCan
Menu
Back to cohort
Record W1597293121 · doi:10.1186/1710-1492-10-s2-a8

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria

2014· article· en· W1597293121 on OpenAlexaffvenueabout
Jennifer Forgie, Stephanie Santucci, Diana Pham, Geneviève Gavigan, Melanie D. Pratt, Simone Fahim, John W. O’Quinn, William H. Yang

Bibliographic record

VenueAllergy Asthma and Clinical Immunology · 2014
Typearticle
Languageen
FieldMedicine
TopicUrticaria and Related Conditions
Canadian institutionsUniversity of OttawaOttawa Allergy Research Corporation
Fundersnot available
KeywordsOmalizumabChronic urticariaMedicineDermatologyIntensive care medicineImmunoglobulin EImmunologyAntibody

Abstract

fetched live from OpenAlex

Chronic spontaneous urticaria (CSU) is a condition, lasting at least 6 months, where patients experience frequent episodes of red, itchy hives and/or angioedema with no apparent external trigger. For approximately 30-50% of patients this condition can resolve spontaneously but has been known to persist for years. CSU can have a major impact on a patient’s quality of life as it can affect daily activities, sleep, emotional wellbeing and social interactions. In March 2014, omalizumab was approved in Europe and eight other countries for the treatment of CSU in patients with inadequate response to H 1 -antihistamines at approved doses. However, as yet there is no approved indication for its use in CSU in Canada and the US. We report on the effectiveness of omalizumab as a treatment option for difficult-to-treat CSU in our clinic. After receiving a diagnosis of CSU with inadequate response to H 1 -antihistamines, and oral prednisone, patients completed a quality of life (QoL) questionnaire prior to beginning treatment with omalizumab. Patients were requested to complete the QoL questionnaires every two weeks throughout the treatment and, in addition, were monitored closely for clinical response. A total of 10 patients, who started on omalizumab for CSU were evaluated. All were taking H 1 -antihistamines prior to treatment with 8 out of the 10 patients able to decrease or stop the use of H 1 - antihistamines after the 3 dose of omalizumab. The results of the questionnaires indicated a 15% improvement in QoL with an accompanying 18% decrease in the symptom score. Of the 10 patients, 9 indicated an overall improvement in their symptoms while only 6 had an overall improvement in their QoL. Omalizumab is an effective therapy in difficult-to-treat CSU in our tertiary community based allergy and asthma clinic.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.889
Threshold uncertainty score0.387

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.294
Teacher spread0.284 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes3
Has abstractyes

Explore more

Same venueAllergy Asthma and Clinical ImmunologySame topicUrticaria and Related ConditionsFrench-language works237,207